MDCX · Medicus Pharma Ltd.
$0.26
-0.01 (-3.48%)
At close · Jul 30
Going-concern doubt
— flagged May 14, 2026
Substantial doubt about the company's ability to continue as a going concern.
“This uncertainty, along with the Company's history of losses, indicates that substantial doubt exists about the Company's ability to continue as a going concern within one year after the date that the financial statements are issued.”View the 10-Q filed May 14, 2026
Market Cap
$14.88M
Shares
56.66M
Income-statement, balance-sheet and cash-flow figures extracted from the company's SEC filings — 10-K annual and 10-Q quarterly reports — and standardised for comparison across periods.
Net Income
-$47.28M
-323.8%
FY2025
Diluted EPS
-$2.74
-136.2%
FY2025
Operating Cash Flow
-$22.78M
-122.3%
FY2025
Chart any reported metric, KPI or segment over time — the full statement history lives here
Search above to add metrics — fundamentals, product and segment revenue, company KPIs, valuation.
| Line Item | TTM | FY2025 | FY2024 | FY2023 |
|---|---|---|---|---|
| — | -$197.38K | $25.39K | — | |
| $8.42M | $7.72M | $3.53M | $193.58K | |
| $20.69M | $17.92M | $7.65M | $4.54M | |
| $37.83M | $34.36M | $11.18M | $4.73M | |
| -$37.83M | -$34.36M | -$11.18M | -$4.73M | |
| -$1.55M | -$1.09M | $25.39K | -$584.82K | |
| — | $0 | $0 | $0 | |
| -$51.22M | -$47.28M | -$11.16M | -$5.31M | |
| — | -$146 | $0 | — | |
| — | -$47.28M | -$11.16M | -$5.31M | |
| — | -$47.29M | -$11.16M | — | |
| USD/shares | — | -$2.74 | -$1.16 | -$1.53 |
| USD/shares | — | -$2.74 | -$1.16 | -$1.53 |
| shares | — | 17.28M | 9.62M | 3.48M |
| shares | — | 17.28M | 9.62M | 3.48M |
Values reflect the latest filing (restatements included); per-share figures on today's split basis. Click a value for its source filing.
TTM: trailing twelve months through the latest reported quarter — flows sum the last four quarters, balances take the latest.
Price & Valuation
Multiples computed on the strict TTM/EV methodology — today's snapshot against peers, and each ratio recomputed as of past filing dates.
Valuation
EV/Revenue
—
Drug Manufacturers - General median 4.42×
EV/EBIT
—
P/E (TTM)
—
Drug Manufacturers - General median 24.74×